Stock-Based Compensation |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Share-Based Payment Arrangement [Abstract] | |
| Stock-Based Compensation |
2026 Equity Incentive Plan
On May 31, 2026, the Company’s Board of Directors adopted the Curanex Pharmaceuticals Inc 2026 Equity Incentive Plan (the “2026 Plan”), which was approved by the Company’s stockholders on June 11, 2026. The 2026 Plan permits the grant of stock options, restricted stock, restricted stock units and other stock-based awards to employees, directors and consultants of the Company. An aggregate of shares of common stock, par value $ per share, are reserved and available for issuance under the 2026 Plan, representing approximately 20.1% of the shares of common stock issued and outstanding as of June 30, 2026. The 2026 Plan is administered by the Board of Directors, or a committee designated by the Board, which determines the recipients, types, terms, vesting conditions and, where applicable, exercise prices of awards. The number of shares reserved under the 2026 Plan is subject to proportionate adjustment in the event of a stock split, reverse stock split, stock dividend, recapitalization or similar change in the Company’s capitalization.
On July 21, 2026, the Company filed a Registration Statement on Form S-8 with the Securities and Exchange Commission registering of the shares of common stock reserved for issuance under the 2026 Plan, representing approximately 10.58% of the shares of common stock issued and outstanding as of the date of filing. The Registration Statement became effective upon filing in accordance with Rule 462 under the Securities Act of 1933, as amended (the “Securities Act”). As of September 30, 2026, the remaining shares reserved under the 2026 Plan had not been registered. See Note 10 for the subsequent registration.
During the third quarter of 2026, the Company granted and issued shares of common stock to six nonemployee consultants under the 2026 Plan. The grants comprised shares effective July 26, 2026, shares effective July 27, 2026 and shares effective August 7, 2026. The shares were issued in two batches of on July 27 and on August 7, 2026. The awards were fully earned on the respective effective dates, without time-based vesting, and are nonrefundable and nonforfeitable except for specified fraud, material breach, misconduct or legal provisions.
The grant-date fair value of these awards was $, based on split-adjusted closing share prices of $, $ and $ for the July 26, July 27 and August 7 grants, respectively. The July 26 grant date was a non-trading day; the July 24 closing price was used. The shares compensate two consultants for strategic business-development and licensing services over one-year terms and four consultants for Australian clinical trial feasibility services over six-month terms.
The Company recognized consulting expense of $ for both the three and nine months ended September 30, 2026, comprising $ within general and administrative expenses and $ within research and development expenses. The remaining $ was recorded within prepaid expenses, including $ for business-development services and $ for clinical-feasibility services. The costs are recognized on a straight-line basis over the contractual service periods as services are received. All of the awards were vested; the prepaid balance represents future services rather than unvested compensation.
Other Stock-Based Compensation
On March 18, 2026, the Company issued an aggregate of shares of common stock to Dr. Huijuan Zhong as additional compensation pursuant to an employment arrangement entered into in June 2024 (see Note 7, Shareholders’ Equity). Following the Company’s initial public offering, the Company issued the full shares in a single issuance, and no further service-based forfeiture conditions remained after issuance. All shares were vested upon issuance. The shares were valued at $ per share, the closing price of the Company’s common stock on March 17, 2026 as reported on Nasdaq. The Company recognized stock-based compensation expense of $ and $ within general and administrative expenses for the three and nine months ended September 30, 2026, respectively, and $ for the three and nine months ended September 30, 2025.
|